Dr Richard Rebello
Honorary Fellow
The Sir Peter MacCallum Department of Oncology
46 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Abstract 427: PMR-116, a second-generation RNA polymerase I inhibitor displaying therapeutic efficacy in a broad spectrum of malignancies.
DOI: 10.1158/1538-7445.am2026-4272026
Journal article
A0396 Tumour cell evolution within patient-derived models of localised hereditary prostate cancer
DOI: 10.1016/s0302-2838(26)00451-32026
Journal article
Patient-derived primary prostate cancer epithelial cultures for studying prostate cancer cell evolution under hypoxia.
DOI: 10.1200/jco.2026.44.7_suppl.3972025
Journal article
762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
DOI: 10.1016/j.annonc.2025.10.11772025
Journal article
Pathologist-initiated whole genome and transcriptome sequencing demonstrates diagnostic utility in resolving difficult-to-diagnose tumors
DOI: 10.1186/s13073-025-01534-52025
Journal article
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary
DOI: 10.1038/s41467-025-59661-x2021
Research grants (other domestic)
Screening for Genetic Vulnerabilities in CHR8Q-amplified Prostate Cancer
RECENT SCHOLARLY WORKS
2024
Journal article
Unravelling mutational signatures with plasma circulating tumour DNA
DOI: 10.1038/s41467-024-54193-22024
Conference Proceedings
Understanding the Clinical and Molecular Phenotype of Cancer of Unknown Primary (CUP) with a Lung Cancer Profile
DOI: 10.1200/jco.2025.43.16_suppl.e205672024
Journal article
76P Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
DOI: 10.1016/j.annonc.2024.08.0842024
Conference Proceedings
Clinical impact of molecular profiling in the national prospective cohort Solving Unknown Primary Cancer (SUPER) study.
DOI: 10.1200/JCO.2024.42.16_suppl.3056